menu
    • menu
    [{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Yuyu Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"YP-P10","moa":"Cytokines\/Chemokine","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Yuyu Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Yuyu Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Yuyu Pharma \/ Inapplicable"},{"orgOrder":0,"company":"YD Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Imatinib Mesylate","moa":"ABL1","graph1":"Ophthalmology","graph2":"Phase II","graph3":"YD Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"YD Life Science \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"YD Life Science \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Yuyu Pharma

                            South Korea arrow
                            Pharmex
                            Not Confirmed

                            Yuyu Pharma

                            South Korea arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YP-P10

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Yuyu Pharma Unveiled the Results of Its Mechanism of Action and Head-To- Head Studies for Its Dry Eye Treatmen...

                            Details : YP-P10 is a novel, patented, synthetic peptide with anti-inflammatory properties, which reduces Th17 cells and is being explored for the potential treatment of dry eye disease (DED).

                            Product Name : YP-P10

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 27, 2023

                            Lead Product(s) : YP-P10

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Yuyu Pharma

                            South Korea arrow
                            Pharmex
                            Not Confirmed

                            Yuyu Pharma

                            South Korea arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YP-P10

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Yuyu Pharma Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating YP-P10 Ophthalmic Solution f...

                            Details : YP-P10, opthalmic solution, a novel and patented synthetic peptide with anti-inflammatory and wound healing properties to treat patients with dry eye disease (DED).

                            Product Name : YP-P10

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            July 20, 2022

                            Lead Product(s) : YP-P10

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Yuyu Pharma

                            South Korea arrow
                            Pharmex
                            Not Confirmed

                            Yuyu Pharma

                            South Korea arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : YP-P10

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Yuyu Pharma Attendance at European Pharmaceutical Conference

                            Details : Preclinical data show that YP-P10 was a more active immunomodulator than lifitegrast in lowering pro-inflammatory cytokines and chemokines production in human peripheral blood mononuclear cells (PBMCs) when stimulated by lipopolysaccharide (LPS)

                            Product Name : YP-P10

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 11, 2022

                            Lead Product(s) : YP-P10

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            YD Life Science

                            South Korea arrow
                            Pharmex
                            Not Confirmed

                            YD Life Science

                            South Korea arrow
                            Pharmex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Imatinib Mesylate

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            YD Life Science Proves Efficacy Of Diabetic Treatment

                            Details : Post-dose vision in all YD-312 dose groups compared with pre-dose was statistically significant, visual acuity was maintained, or the treatment efficiency improved significantly compared to the placebo group, the official noted.

                            Product Name : YD-312

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 13, 2020

                            Lead Product(s) : Imatinib Mesylate

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth